Recruiting

CSF Flow Detection

Sponsor:

Rhaeos, Inc.

Code:

NCT07478926

Conditions

Hydrocephalus

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Rhaeos Shunt Monitoring System

Study Details

Brief summary:

This study is evaluating a new, noninvasive device designed to detect whether cerebrospinal fluid (CSF) is flowing through a surgically implanted shunt. CSF shunts are commonly used to treat hydrocephalus, but it can be difficult to tell whether a shunt is working properly without invasive testing or imaging that does not directly measure flow.

The study device is a small, wireless sensor placed on the skin over the shunt tubing, typically near the collarbone. It uses gentle, controlled warmth to measure temperature changes that indicate whether fluid is flowing inside the shunt. The device does not break the skin and does not change a participant's medical care.

This study will enroll children and adults who already have a CSF shunt and who do not have new or worsening symptoms of shunt malfunction. All participants will have a measurement taken while their shunt valve is at its usual prescribed setting. Some participants with programmable shunt valves will also have a second measurement taken after their valve is temporarily adjusted to a setting intended to stop or greatly reduce flow ("virtual off"). After this measurement, the valve will be returned to its prescribed setting.

The study device results will not be shown to participants or their medical providers and will not be used to make treatment decisions. The goal of the study is to determine how well the device can distinguish between shunts that are allowing flow and those that are not.

Participants will be monitored for a short period after device use and, if applicable, after any valve adjustment. The main risks of participation are mild skin irritation from the adhesive or temporary symptoms related to valve adjustment. Participants are not expected to receive a direct medical benefit, but the information gained may help improve future diagnosis of shunt function.

Conditions

Hydrocephalus

Study ID

NCT07478926

Start date

Jan 27, 2026

Status verified date

Mar, 2026

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Inclusion and Exclusion Criteria for Roll-In Subjects Inclusion criteria

  • Existing ventricular CSF shunt with an available "virtual off" setting which can be programmed noninvasively
  • Region of intact skin overlying an unambiguously identifiable palpable chronically indwelling ventricular shunt which crosses the clavicle and is appropriate in size for application of the study device
  • Signed informed consent by subject or a parent or legal guardian, health care agent, or surrogate decision maker (according to local statutes)
  • Subject-reported or documented history of successful valve adjustment(s)

Inclusion and Exclusion Criteria for Main Study Subjects

Inclusion criteria

  • Existing ventricular CSF shunt
  • Region of intact skin overlying an unambiguously identifiable palpable chronically indwelling ventricular shunt which crosses the clavicle and is appropriate in size for application of the study device
  • Signed informed consent by subject or a parent, legal guardian, health care agent, or surrogate decision maker (according to local statutes)

Subjects with planned "virtual off" measurement:

-Existing ventricular CSF shunt with an available "virtual off" setting which can be programmed noninvasively

Subjects with planned adjustment to the "virtual off" setting only:

-Subject-reported or documented history of successful valve adjustment(s)

Exclusion Criteria:

Exclusion criteria

  • Presence of more than one distal shunt catheter in the study device measurement region
  • Presence of an interfering open wound or edema in the study device measurement region
  • Shunt is difficult to palpate, or the shunt depth at the device measurement location is deeper than 5 mm from the skin surface via ultrasound measurement
  • Shunt valve is set to an opening pressure of >= 300 mm H2O, or the shunt system is otherwise set to substantially prevent shunt flow (e.g. Certas Plus valve programmed to a setting of 8 or a ligated shunt)
  • Investigator judges that the subject is likely to be shunt independent (e.g. does not require a functional shunt for management of hydrocephalus)
  • Subject has more than one intact and presumed functional distal catheter
  • Subject-reported or documented history of serious adverse skin reactions to silicone-based adhesives
  • Subject-reported new or worsening symptoms of a possible shunt malfunction in the prior 7 days
  • Use of the study device would interfere with standard patient care, or emergency surgery that cannot be delayed, or participation in the study will interfere with, or be detrimental to, administration of optimal healthcare to the subject
  • Prior enrollment in this study
  • Participation in any other investigational procedural, pharmaceutical, and/or device study that may influence the collection of valid data under this study

Exclusion Criteria for Main Study Subjects Exclusion criteria

  • Presence of more than one distal shunt catheter in the study device measurement region
  • Presence of an interfering open wound or edema in the study device measurement region
  • Shunt is difficult to palpate, or the shunt depth at the device measurement location is deeper than 5 mm from the skin surface via ultrasound measurement
  • Subject-reported or documented history of serious adverse skin reactions to silicone-based adhesives
  • Subject-reported new or worsening symptoms of a possible shunt malfunction in the prior 7 days
  • Use of the study device would interfere with standard patient care, or emergency surgery that cannot be delayed, or participation in the study will interfere with, or be detrimental to, administration of optimal healthcare to the subject
  • Prior enrollment in this study
  • Participation in any other investigational procedural, pharmaceutical, and/or device study that may influence the collection of valid data under this study
  • Previous participation in a Rhaeos clinical study in which the study device (current generation) was used to acquire measurement data

Subjects with planned "valve normal" measurements:

  • Shunt system is set to substantially prevent shunt flow (e.g. ligated shunt)
  • Investigator judges that the subject is likely to be shunt independent (e.g. does not require a functional shunt for management of hydrocephalus)
  • Subject has more than one intact and presumed functional distal catheter

Study Design

Enrollment

55 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

other: CSF Shunt Flow Assessment with Wireless Thermal Device

Participants undergo noninvasive assessment of cerebrospinal fluid (CSF) shunt flow using a wireless thermal flow detection device placed on the skin overlying the shunt tubing. All participants have a measurement performed at their prescribed shunt valve setting. Participants with programmable valves capable of a manufacturer-reported "virtual off" setting may undergo an additional measurement after temporary valve adjustment to reduce or stop CSF flow, followed by return of the valve to the prescribed setting. Device results are encoded and blinded to participants and clinical staff and are not used for clinical decision-making. Participants are monitored for adverse events during and after device use.

Interventions

Rhaeos Shunt Monitoring System

characters, and fully aligned with your protocol: The intervention consists of use of a noninvasive, wireless thermal flow detection device to assess cerebrospinal fluid (CSF) flow in an existing implanted shunt. The device is externally applied to intact skin over the shunt tubing, typically near the clavicle, and delivers controlled, imperceptible thermal energy while measuring resulting temperature gradients associated with CSF flow. Measurements are performed using a sponsor-provided tablet application that encodes results to maintain blinding. In some participants with programmable shunt valves, measurements are obtained under both prescribed flow-permissive settings and a temporary manufacturer-reported "virtual off" valve setting, after which the valve is returned to the prescribed setting. Device data are collected for research purposes only and are not used to guide clinical care.

Primary outcome measure

  • Sensitivity and Specificity [ Time Frame: Day 1 ]

Central Contacts and Locations

Central contacts

Anna Somera

855-814-3569info@rhaeos.com

Locations

OSF Healthcare

Recruiting

Peoria, Illinois, United States, 61602

Contacts

Anna Somera

855-814-3569info@rhaeos.com

Principal Investigator:

Richard Webb, PhD

More Information

Sponsor

Rhaeos, Inc.

Last update posted

Mar 18, 2026

Last verified

Mar, 2026

Keywords

  • hydrocephalus
  • wearable
  • shunt
  • valve

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Rhaeos, Inc. on 2026-03-18.